| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Rush-Presbyterian St. Luke's Medical Center, Chicago, IL.
Using case-control methodology, we assessed prevalence and duration of exposure to putative risk factors for rapid progression of Parkinson's disease (PD) in patients not taking levodopa or direct dopamine agonists. We identified 31 patients termed "rapidly progressive" who were stage I or II (Hoehn and Yahr) on their first visit to our center and who progressed to stage HI during the study period; we pair-matched this group with 31 "slowly progressive" patients who had the same symptom duration and the same Hoehn and Yahr stage at study entry, but whose parkinsonism did not progress to stage III during the study. Only age of PD onset was associated with different rates of PD progression; older patients at PD onset progressed more rapidly than younger patients.
Address correspondence and reprint requests to Dr. Goetz, Rush-Presbyterian St. Luke's Medical Center, 1725 West Harrison Street, Chicago, IL 60612.
Received June 25, 1987. Accepted for publication in final form June 2, 1988.
This article has been cited by other articles:
|
|
 |
|
  A. H. Rajput, A. Voll, M. L. Rajput, C. A. Robinson, and A. Rajput Course in Parkinson disease subtypes: A 39-year clinicopathologic study Neurology, July 21, 2009; 73(3): 206 - 212. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Levy The Relationship of Parkinson Disease With Aging Arch Neurol, September 1, 2007; 64(9): 1242 - 1246. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Alves, T. Wentzel-Larsen, D. Aarsland, and J. P. Larsen Progression of motor impairment and disability in Parkinson disease: A population-based study Neurology, November 8, 2005; 65(9): 1436 - 1441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S J G Lewis, T Foltynie, A D Blackwell, T W Robbins, A M Owen, and R A Barker Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach J. Neurol. Neurosurg. Psychiatry, March 1, 2005; 76(3): 343 - 348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Levy, E. D. Louis, L. Cote, M. Perez, H. Mejia-Santana, H. Andrews, J. Harris, C. Waters, B. Ford, S. Frucht, et al. Contribution of Aging to the Severity of Different Motor Signs in Parkinson Disease Arch Neurol, March 1, 2005; 62(3): 467 - 472. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Jellinger Parkinson Disease With Old-Age Onset Arch Neurol, December 1, 2003; 60(12): 1814 - 1815. [Full Text] [PDF]
|
|
|
|
|
|
C. Marras, P. Rochon, and A. E. Lang Predicting Motor Decline and Disability in Parkinson Disease: A Systematic Review Arch Neurol, November 1, 2002; 59(11): 1724 - 1728. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A Hely, J. G L Morris, R. Traficante, W. G J Reid, D. J O'Sullivan, and P. M Williamson The Sydney multicentre study of Parkinson's disease: progression and mortality at 10 years J. Neurol. Neurosurg. Psychiatry, September 1, 1999; 67(3): 300 - 307. [Abstract] [Full Text]
|
|
|
|
|
|
W. C. Koller, J. T. Hutton, E. Tolosa, and R. Capilldeo Immediate-release and controlled-release carbidopa/levodopa in PD : A 5-year randomized multicenter study Neurology, September 1, 1999; 53(5): 1012 - 1012. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Mitchell, E. A. Sullivan, and L. A. Lipsitz Exclusion of Elderly Subjects From Clinical Trials for Parkinson Disease Arch Neurol, November 1, 1997; 54(11): 1393 - 1398. [Abstract] [PDF]
|
|
|
|
|
|
M. P. McDermott, J. Jankovic, J. Carter, S. Fahn, S. Gauthier, C. G. Goetz, L. I. Golbe, W. Koller, A. E. Lang, C. W. Olanow, et al. Factors Predictive of the Need for Levodopa Therapy in Early, Untreated Parkinson's Disease Arch Neurol, June 1, 1995; 52(6): 565 - 570. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
